EMMAC Life Sciences is a medical cannabis company founded in 2018 and based in London, England. The company focuses on integrating the latest scientific research with advanced cultivation, extraction, and production methodologies to develop medical cannabis, hemp, and derivative products. EMMAC has made significant strides in establishing unique supply and distribution partnerships across Europe, positioning itself as a leader in the production and supply of medical cannabis. In addition to its commercial endeavors, the company is also actively involved in driving research into the medical benefits of cannabis, showcasing a commitment to innovation and scientific advancement.
EMMAC's recent investment round saw a £15.00M Convertible Note investment on 16 December 2020, with Measure 8 Venture Partners participating as the investor. This injection of funding reflects investor confidence in the company's strategic vision and potential for growth in the burgeoning medical cannabis industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Convertible Note | £15.00M | 1 |
|
16 Dec 2020 |
| Convertible Note | Unknown | 1 |
|
01 Jun 2019 |
| Venture Round | $5.33M | - | 20 Dec 2018 |
No recent news or press coverage available for EMMAC Life Sciences.
We care about your data, and we'd love to use cookies make your experience better.
